The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second-line outcomes in metastatic renal cell carcinoma: The role of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors after first-line immunotherapy.
 
David Maj
No Relationships to Disclose
 
Martin Zarba
No Relationships to Disclose
 
Connor Wells
No Relationships to Disclose
 
Marc Eid
No Relationships to Disclose
 
Razane El Hajj Chehade
No Relationships to Disclose
 
Zeynep Irem Ozay
No Relationships to Disclose
 
Joe Dib
No Relationships to Disclose
 
Ulka Vaishampayan
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Janssen Oncology; Merck Serono; Mural; Pfizer; Pfizer/Astellas; Sumitomo Pharma Oncology
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Arnoud Templeton
Honoraria - Bayer (Inst); Janssen
Consulting or Advisory Role - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb/Pfizer (Inst); Ipsen (Inst); Merck; MSD; MSD (Inst); Pfizer (Inst); Pfizer (Inst); Sandoz (Inst)
Travel, Accommodations, Expenses - Orion Health; Roche
 
Naveen Basappa
Stock and Other Ownership Interests - illumiSonics
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Eisai; Ipsen; Janssen; Merck; Pfizer; Seagen; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Seagen
Research Funding - Ipsen (Inst)
Travel, Accommodations, Expenses - Eisai; Ipsen; Johnson & Johnson/Janssen; Pfizer
 
Shirley Wong
No Relationships to Disclose
 
Andrew Weickhardt
No Relationships to Disclose
 
Aly-Khan Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)
 
Ravindran Kanesvaran
Honoraria - Astellas Pharma; Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst)
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Janssen Oncology (Inst); MSD Oncology; Novartis (Inst); pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; MSD Oncology
 
Guillermo de Velasco
Honoraria - Astellas Pharma; BMS; Ipsen; Pfizer
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - BMS; BMS; Roche
 
Martin Angel
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Toni Choueiri
No Relationships to Disclose
 
Daniel Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)